Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

2.12
-0.0300-1.40%
Pre-market: 2.09-0.0300-1.42%06:07 EDT
Volume:557.81K
Turnover:1.18M
Market Cap:102.41M
PE:-1.39
High:2.15
Open:2.15
Low:2.09
Close:2.15
Loading ...

Cassava Sciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
28 May

Cassava Sciences Q1 EPS $(0.48) Down From $(0.43) YoY

Benzinga
·
08 May

Cassava Sciences Inc - Reduces Workforce by 33% in Q1 2025

THOMSON REUTERS
·
08 May

Cassava Reports Q1 2025 Financials Results, Provides Business Update

THOMSON REUTERS
·
08 May

Cassava Sciences Inc. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy

Reuters
·
01 May

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

GlobeNewswire
·
01 May

Cassava Sciences CMO James Kupiec to Retire

MT Newswires Live
·
22 Apr

Cassava Sciences Chief Medical Officer Kupiec Retires

Dow Jones
·
22 Apr

Cassava Sciences Announces Leadership Changes Amid Strategic Shift

TIPRANKS
·
22 Apr

Cassava Sciences chief medical officer James Kupiec to retire

TIPRANKS
·
22 Apr

Cassava Announces Retirement of Chief Medical Officer, DR. Jim Kupiec, and Appointment of DR. Jack Moore as Senior Vice President, Clinical Development

THOMSON REUTERS
·
22 Apr

Press Release: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Dow Jones
·
22 Apr

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround

Zacks
·
01 Apr

Is the Future Bleak for SAVA Stock Following Another Setback?

Zacks
·
31 Mar

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Reuters
·
27 Mar

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

Zacks
·
26 Mar

Equity Markets Close Higher, Weak Consumer Confidence Data Lifts Fed Easing Hopes

MT Newswires Live
·
26 Mar

Top Midday Decliners

MT Newswires Live
·
26 Mar

Cassava Sciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar

Cassava Sciences’ Alzheimer’s Drug Trials Fall Short, Neutral Rating Maintained Amid Uncertainties

TIPRANKS
·
25 Mar